Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01248949 · BASELINE

Baseline characteristics

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors · Source last updated 2017-03-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      42
    2. group Id
      BG001
      value
      16
    3. group Id
      BG002
      value
      38
    4. group Id
      BG003
      value
      13
    5. group Id
      BG004
      value
      7
    6. group Id
      BG005
      value
      116
    units
    Participants
groups
  1. description
    Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG000
    title
    MEDI3617 SINGLE AGENT TOTAL
  2. description
    Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG001
    title
    MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
  3. description
    Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
    id
    BG002
    title
    MEDI3617 + BEVACIZUMAB Q2W TOTAL
  4. description
    Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
    id
    BG003
    title
    MEDI3617 + PACLITAXEL TOTAL
  5. description
    Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG004
    title
    MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
  6. description
    Total of all reporting groups
    id
    BG005
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          12.4
          value
          61.4
        2. group Id
          BG001
          spread
          11.9
          value
          57.4
        3. group Id
          BG002
          spread
          11.2
          value
          57.7
        4. group Id
          BG003
          spread
          12.7
          value
          60.4
        5. group Id
          BG004
          spread
          12.3
          value
          56.7
        6. group Id
          BG005
          spread
          11.9
          value
          59.2
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          18
        4. group Id
          BG003
          value
          8
        5. group Id
          BG004
          value
          5
        6. group Id
          BG005
          value
          65
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          15
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          20
        4. group Id
          BG003
          value
          5
        5. group Id
          BG004
          value
          2
        6. group Id
          BG005
          value
          51
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population included all participants who receive any treatment with MEDI3617.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      42
    2. group Id
      BG001
      value
      16
    3. group Id
      BG002
      value
      38
    4. group Id
      BG003
      value
      13
    5. group Id
      BG004
      value
      7
    6. group Id
      BG005
      value
      116
    units
    Participants
groups
  1. description
    Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG000
    title
    MEDI3617 SINGLE AGENT TOTAL
  2. description
    Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG001
    title
    MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
  3. description
    Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
    id
    BG002
    title
    MEDI3617 + BEVACIZUMAB Q2W TOTAL
  4. description
    Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
    id
    BG003
    title
    MEDI3617 + PACLITAXEL TOTAL
  5. description
    Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
    id
    BG004
    title
    MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
  6. description
    Total of all reporting groups
    id
    BG005
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          12.4
          value
          61.4
        2. group Id
          BG001
          spread
          11.9
          value
          57.4
        3. group Id
          BG002
          spread
          11.2
          value
          57.7
        4. group Id
          BG003
          spread
          12.7
          value
          60.4
        5. group Id
          BG004
          spread
          12.3
          value
          56.7
        6. group Id
          BG005
          spread
          11.9
          value
          59.2
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          18
        4. group Id
          BG003
          value
          8
        5. group Id
          BG004
          value
          5
        6. group Id
          BG005
          value
          65
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          15
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          20
        4. group Id
          BG003
          value
          5
        5. group Id
          BG004
          value
          2
        6. group Id
          BG005
          value
          51
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population included all participants who receive any treatment with MEDI3617.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice